SEC Pushes Back Decisions on PENGU and Cardano ETFs as October Deadlines Loom

The U.S. Securities and Exchange Commission (SEC) has once again slowed the progress of cryptocurrency exchange-traded funds, postponing decisions on the Canary spot PENGU ETF and Grayscale’s spot Cardano ETF. Both filings had been viewed as potential milestones for broader crypto adoption in the U.S., but regulators opted to extend the review process.

The latest deferrals highlight the SEC’s ongoing hesitation around crypto-linked financial products, as it weighs concerns over investor protection, transparency, and the possibility of market manipulation. According to official filings, the agency requires additional time to assess whether these ETFs meet the necessary standards for fair valuation and market oversight.

Two critical deadlines now define the regulatory calendar: the PENGU ETF will be revisited on October 12, 2025, with options to approve, disapprove, or extend once more. By contrast, the Grayscale Cardano ETF faces a final deadline of October 26, 2025 under its 19b-4 filing—meaning the SEC must issue a definitive ruling without further extensions.

Both applications are designed to provide U.S. investors with direct exposure to cryptocurrency prices through traditional financial markets, bypassing the complexities of self-custody. Market observers have closely tracked these filings as indicators of whether digital assets are edging closer to mainstream legitimacy.

While the SEC’s notices avoid direct commentary, the extensions underscore its preference for a measured approach. The agency’s stance mirrors prior delays involving Bitcoin and Ethereum products, signaling that regulators remain unconvinced the market is fully prepared for broader ETF adoption.

For investors, the decision means continued uncertainty. Proponents argue spot crypto ETFs would boost transparency and accessibility, while critics warn of risks in a still-maturing market. Until the SEC reaches a conclusion this fall, firms like Canary and Grayscale remain in limbo, waiting to see whether their products will finally clear regulatory hurdles.